Compare NCNO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | GH |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 14.1B |
| IPO Year | 2020 | 2018 |
| Metric | NCNO | GH |
|---|---|---|
| Price | $26.16 | $101.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 21 |
| Target Price | $33.93 | ★ $96.48 |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 12-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $586,485,000.00 | ★ $902,569,000.00 |
| Revenue This Year | $11.87 | $35.00 |
| Revenue Next Year | $7.87 | $26.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.14 | ★ 30.38 |
| 52 Week Low | $18.75 | $29.91 |
| 52 Week High | $35.54 | $112.43 |
| Indicator | NCNO | GH |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 52.97 |
| Support Level | $25.52 | $96.28 |
| Resistance Level | $26.36 | $104.75 |
| Average True Range (ATR) | 0.76 | 3.42 |
| MACD | 0.17 | -0.69 |
| Stochastic Oscillator | 88.46 | 51.64 |
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.